About the Case Study
Acquired Thrombotic Thrombocytopenic Purpura (aTTP) is a rare disease that, when left untreated leads to a 95% morbidity rate. However, 80-90% of patients that receive treatment respond favorably. In this Phase III study, Pharm-Olam International is partnering with a progressive sponsor company to assist in finding a better solution for suffering with aTTP.
Sites & Locations:
91+ Sites across 25 countries in Asia, Eastern and Western Europe and North America
Services Provided:
- Site Identification & Selection
- Regulatory
- Clinical & Medical Monitoring
- Project Management
- Medical Writing
